Atrium Health Cabarrus
- Type
- Teaching hospital
- Where
- CONCORD, NC
- Medicare CCN
- 340001
- Received
- $6,357,966 in 636 records, 2025 ($535,138 general, $5,822,827 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 168 | $535,138 |
| 2025 | Research payment | 468 | $5,822,827 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 468 | $5,822,827 |
| Space rental or facility fees (teaching hospital only) | 61 | $170,623 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 67 | $101,540 |
| Education | 15 | $81,417 |
| Royalty or License | 4 | $72,670 |
| Grant | 10 | $52,500 |
| Long term medical supply or device loan | 1 | $41,500 |
| Debt forgiveness | 5 | $12,715 |
| Consulting Fee | 2 | $2,000 |
| Food and Beverage | 3 | $171 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | AngioDynamics, Inc. | $41,500 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,963 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Stryker Corporation | $3,569 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Stryker Corporation | $1,634 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2025 | |
| 2025-12-30 | HEARTFLOW, INC. | $11,760 | Education | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-12-30 | HEARTFLOW, INC. | $11,760 | Education | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-12-30 | HEARTFLOW, INC. | $5,040 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-12-30 | HEARTFLOW, INC. | $5,040 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-12-23 | Regeneron Pharmaceuticals, Inc. | $5,746 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-12-23 | Regeneron Pharmaceuticals, Inc. | $4,398 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-12-23 | Regeneron Pharmaceuticals, Inc. | $2,741 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-12-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,965 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $4,438 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,170 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $916 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $329 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $329 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-18 | Genentech, Inc. | $38,128 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | T DM1 Atezolizumab in high risk HER2 patients with residual disease | 2025 |
| 2025-12-18 | Smith+Nephew, Inc. | $2,520 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Sports Med Knee | 2025 | |
| 2025-12-18 | Novo Nordisk AS | $1,735 | Research payment | Cash or cash equivalent | Drug | 4202-HEM-301 | 2025 |
| 2025-12-18 | Abbott Laboratories | $1,000 | Consulting Fee | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart | 2025 | |
| 2025-12-17 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-12-17 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-12-16 | Travere Therapeutics, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2025 | |
| 2025-12-15 | Genentech, Inc. | $11,622 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A phase III trial in adjuvant HER2 BC pts | 2025 |
| 2025-12-12 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 Device, Heart Failure | NCT04069156--The ARIES HeartMate 3 Pump IDE Study | 2025 |
| 2025-12-11 | ABBVIE INC. | $6,212 | Research payment | Cash or cash equivalent | A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in | 2025 | |
| 2025-12-11 | E.R. Squibb & Sons, L.L.C. | $3,466 | Research payment | Cash or cash equivalent | ORENCIA Biological, Immunology | An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis | 2025 |
| 2025-12-10 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-12-08 | F. Hoffmann-La Roche AG | $1,500 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-04 | ABBVIE INC. | $14,362 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi | 2025 | |
| 2025-12-03 | Siemens Medical Solutions USA, Inc. | $10,000 | Grant | Cash or cash equivalent | IntelliBlate Microwave Ablation System Console Device, Oncology | 2025 | |
| 2025-12-03 | Genentech, Inc. | $6,100 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2025 |
| 2025-12-03 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-12-01 | ABBVIE INC. | $3,213 | Research payment | Cash or cash equivalent | First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple | 2025 | |
| 2025-12-01 | Epizyme, Inc. | $2,189 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $2,189 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,989 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $1,747 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $115 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-26 | Roche Products Limited | $6,449 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Morpheus UC | 2025 |
| 2025-11-25 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-25 | Boston Scientific Corporation | $1,210 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROADSTER 3 | 2025 |
| 2025-11-25 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-24 | PFIZER INC. | $796 | Research payment | Cash or cash equivalent | PADCEV Biological, ONCOLOGY | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $8,475 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $8,475 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $8,475 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $8,475 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,783 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,768 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,768 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,768 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,768 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,560 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,423 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,423 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,423 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,423 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,169 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,159 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $1,014 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $891 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $891 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $885 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $876 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $653 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $632 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $632 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $632 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $584 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $584 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $579 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $579 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $572 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $506 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $416 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $379 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $379 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $334 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $326 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $326 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $253 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $253 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $239 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $218 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $218 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $218 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $143 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $143 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $115 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-21 | Regeneron Pharmaceuticals, Inc. | $115 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-11-19 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-19 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 Device, Heart Failure | NCT04069156--The ARIES HeartMate 3 Pump IDE Study | 2025 |
| 2025-11-19 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-11-19 | Genentech, Inc. | $117 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-11-18 | Boston Scientific Corporation | $4,108 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2025 |
| 2025-11-13 | ABBVIE INC. | $63,907 | Research payment | Cash or cash equivalent | A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in | 2025 | |
| 2025-11-13 | Smith+Nephew, Inc. | $2,582 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CLANCY Device, Sports Med Knee | 2025 | |
| 2025-11-12 | Edwards Lifesciences Corporation | $5,269 | Research payment | Cash or cash equivalent | ALLIANCE AVIV 2021-05 | 2025 | |
| 2025-11-12 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-12 | SANOFI US SERVICES INC. | $300 | Research payment | Cash or cash equivalent | CEREZYME Biological, Genetic Disease | Gaucher Disease Registry Protocol | 2025 |
| 2025-11-12 | Abbott Laboratories | $98 | Research payment | Cash or cash equivalent | I-STAT Device, Point of Care | ISM2404009A--Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury | 2025 |
| 2025-11-11 | VERTEX PHARMACEUTICALS INCORPORATED | $261 | Research payment | Cash or cash equivalent | A Long-term Follow-up Study of Subjects with B-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 mo | 2025 | |
| 2025-11-07 | SEAGEN INC. | $18,531 | Research payment | Cash or cash equivalent | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48A | 2025 | |
| 2025-11-07 | Edwards Lifesciences Corporation | $7,936 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2025 | |
| 2025-11-07 | National Marrow Donor Program | $845 | Research payment | Cash or cash equivalent | Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) | 2025 | |
| 2025-11-06 | E.R. Squibb & Sons, L.L.C. | $1,313 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating N | 2025 |
| 2025-11-05 | Abbott Laboratories | $3,176 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-11-05 | Intuitive Surgical, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-11-04 | ABBVIE INC. | $10,569 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi | 2025 | |
| 2025-11-03 | E.R. Squibb & Sons, L.L.C. | $24,301 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | 2025 |
| 2025-11-03 | Genentech, Inc. | $15,720 | Research payment | Cash or cash equivalent | Itovebi Biological, BioOncology | Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | 2025 |
| 2025-11-03 | ABBVIE INC. | $3,213 | Research payment | Cash or cash equivalent | First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple | 2025 | |
| 2025-10-31 | National Marrow Donor Program | $3,000 | Research payment | Cash or cash equivalent | Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a ra | 2025 | |
| 2025-10-31 | Regeneron Pharmaceuticals, Inc. | $2,741 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2025 | |
| 2025-10-30 | Boston Scientific Corporation | $5,000 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-10-30 | Abbott Laboratories | $3,000 | Research payment | Cash or cash equivalent | ESPRIT Device, Vascular | NCT06656364--Esprit BTK Post-Approval Study | 2025 |
| 2025-10-29 | Linde Gas & Equipment Inc. | $594 | Space rental or facility fees (teaching hospital only) | In-kind items and services | LGEREG081 Device, RESPIRATORY | 2025 | |
| 2025-10-28 | Genentech, Inc. | $22,634 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2025 |
| 2025-10-28 | Genentech, Inc. | $1,899 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2025 |
| 2025-10-28 | Abbott Laboratories | $1,000 | Consulting Fee | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart | 2025 | |
| 2025-10-28 | Linde Gas & Equipment Inc. | $594 | Space rental or facility fees (teaching hospital only) | In-kind items and services | LGEREG081 Device, RESPIRATORY | 2025 | |
| 2025-10-23 | AstraZeneca Pharmaceuticals LP | $19,322 | Research payment | Cash or cash equivalent | A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 | 2025 | |
| 2025-10-22 | KLS-Martin L.P. | $19,113 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-10-22 | Insulet Corporation | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-22 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-22 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-21 | Boston Scientific Corporation | $1,209 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2025 |
| 2025-10-20 | Exelixis Inc. | $37,769 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $18,597 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $7,531 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $6,228 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $6,004 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $3,000 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $2,822 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Abbott Laboratories | $1,533 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04177394--MitraClip EXPAND G4 Study | 2025 |
| 2025-10-20 | Exelixis Inc. | $1,200 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $477 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-20 | Exelixis Inc. | $300 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2025 |
| 2025-10-17 | National Marrow Donor Program | $12,560 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-10-16 | ABBVIE INC. | $83,934 | Research payment | Cash or cash equivalent | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $10,891 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $53 | Research payment | Cash or cash equivalent | ALLIANCE AVIV 2021-05 | 2025 | |
| 2025-10-15 | Novo Nordisk AS | $1,735 | Research payment | Cash or cash equivalent | Drug | 4202-HEM-301 | 2025 |
| 2025-10-15 | Linde Gas & Equipment Inc. | $594 | Space rental or facility fees (teaching hospital only) | In-kind items and services | LGEREG081 Device, RESPIRATORY | 2025 | |
| 2025-10-15 | Insulet Corporation | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-14 | HEARTFLOW, INC. | $8,000 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-10-14 | HEARTFLOW, INC. | $4,000 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-10-14 | HEARTFLOW, INC. | $2,000 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-10-13 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-13 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-13 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-10 | National Marrow Donor Program | $350 | Research payment | Cash or cash equivalent | 1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy fo | 2025 | |
| 2025-10-09 | ABBVIE INC. | $6,755 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi | 2025 | |
| 2025-10-09 | ABBVIE INC. | $1,304 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis | 2025 |
| 2025-10-09 | Genentech, Inc. | $273 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2025 |
| 2025-10-08 | Genentech, Inc. | $8,695 | Research payment | Cash or cash equivalent | Itovebi Biological, BioOncology | Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | 2025 |
| 2025-10-08 | ABBVIE INC. | $6,493 | Research payment | Cash or cash equivalent | A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in | 2025 | |
| 2025-10-08 | Alexion Pharmaceuticals, Inc. | $4,400 | Research payment | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Partic | 2025 |
| 2025-10-06 | PFIZER INC. | $1,790 | Research payment | Cash or cash equivalent | PADCEV Biological, ONCOLOGY | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,741 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,741 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,697 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,466 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,236 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,216 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,165 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $1,747 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $1,747 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $1,534 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTO | 2025 |
| 2025-10-02 | ABBVIE INC. | $3,213 | Research payment | Cash or cash equivalent | First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple | 2025 | |
| 2025-10-02 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-01 | Edwards Lifesciences Corporation | $6,822 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2025 | |
| 2025-10-01 | Edwards Lifesciences Corporation | $2,238 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2025 | |
| 2025-10-01 | Genentech, Inc. | $471 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-26 | Stryker Corporation | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CORE Device, NEURO SPINE ENT | 2025 | |
| 2025-09-25 | Getinge USA Sales, LLC | $425 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BASE UNIT SERVO-U Device, CARDIOVASCULAR CARE | 2025 | |
| 2025-09-24 | Epizyme, Inc. | $2,753 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,989 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,989 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
The latest 200 records of 636.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Concord, NC, county Cabarrus County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Concord, NC | County Cabarrus County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 108,719 | 236,133 | 10,730,404 |
| Population, 2020 census P1 | 105,240 | 225,804 | 10,439,388 |
| Median age B01002 | 36.5 | 37.7 | 39.1 |
| Under 18 B01001 | 26.8% | 25.2% | 21.8% |
| 65 and over B01001 | 12.0% | 13.6% | 17.2% |
| Households B11001 | 38,669 | 84,246 | 4,282,345 |
| Foreign born B05002 | 13.5% | 10.8% | 9.1% |
| Median household income B19013 | $86,921 | $89,005 | $72,388 |
| Median family income B19113 | $104,221 | $106,314 | $90,290 |
| Per capita income B19301 | $42,090 | $42,636 | $41,385 |
| Poverty rate B17001 | 9.6% | 9.3% | 13.0% |
| Unemployment rate B23025 | 5.5% | 4.6% | 4.7% |
| Civilian labor force B23025 | 58,255 | 125,285 | 5,336,863 |
| Mean commute (minutes) B08013 | 26.9 | 27.3 | 25.1 |
| Bachelor's degree or higher B15003 | 40.9% | 37.9% | 35.7% |
| Housing units B25001 | 43,142 | 93,691 | 4,895,668 |
| Owner-occupied B25003 | 65.2% | 71.2% | 66.6% |
| Renters B25003 | 34.8% | 28.8% | 33.4% |
| Median home value B25077 | $353,700 | $354,800 | $288,900 |
| Median gross rent B25064 | $1,451 | $1,414 | $1,228 |
| White, not Hispanic B03002 | 49.4% | 57.3% | 60.0% |
| Black B03002 | 22.3% | 18.7% | 20.0% |
| Hispanic or Latino B03002 | 15.8% | 12.7% | 11.3% |
| Asian B03002 | 7.7% | 6.2% | 3.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Concord, NC.
Comments